Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study
Fahim Ebrahimi, Hannes Hagström, Jiangwei Sun, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1374-1384
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 220
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 30
Metabolic dysfunction-associated steatotic liver disease and its link to cancer
Markos Kalligeros, Linda Henry, Zobair M. Younossi
Metabolism (2024) Vol. 160, pp. 156004-156004
Closed Access | Times Cited: 17
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 1
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Amani Elshaer, David M. Chascsa, Blanca Lizaola‐Mayo
Life (2024) Vol. 14, Iss. 7, pp. 844-844
Open Access | Times Cited: 6
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Na Young Lee, Myeung Gi Choi, Eui Jin Lee, et al.
Archives of Pharmacal Research (2024) Vol. 47, Iss. 6, pp. 558-570
Open Access | Times Cited: 5
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
K.F. Au, Ming‐Hua Zheng, Wei‐Jei Lee, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 4, pp. 818-830
Closed Access | Times Cited: 4
Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin
Shiyu Zhou, Ruixuan Chen, Jiao Liu, et al.
Annals of Internal Medicine (2024)
Closed Access | Times Cited: 4
Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis
Qingyan Kong, Diao Kong, Bei Li, et al.
Academic Radiology (2025)
Closed Access
Immune landscape of hepatocellular carcinoma tumor microenvironment identifies a prognostic relevant model
Hongru Cao, Ping Huang, Jiawei Qiu, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e24861-e24861
Open Access | Times Cited: 3
Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration
Aleksandra Bołdys, Łukasz Bułdak
World Journal of Gastroenterology (2024) Vol. 30, Iss. 18, pp. 2387-2390
Open Access | Times Cited: 2
Risk of major adverse liver outcomes among first‐degree relatives of individuals with MASLD
Wen Yang, Fahim Ebrahimi, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1253-1264
Closed Access | Times Cited: 1
Nomogram for predicting 5-year metabolic dysfunction-associated steatotic liver disease risk: retrospective cohort study
Lei Gao, Wenxia Cui, Dinghuang Mu, et al.
Endocrine Connections (2024) Vol. 13, Iss. 8
Open Access | Times Cited: 1
A high reticulocyte count is a risk factor for the onset of metabolic dysfunction-associated steatotic liver disease: Cross-sectional and prospective studies of data of 310,091 individuals from the UK Biobank
Peng‐Cheng Ma, Qimei Li, Ruining Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Renin–angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection
Ruixuan Chen, Shiyu Zhou, Jiao Liu, et al.
Canadian Medical Association Journal (2024) Vol. 196, Iss. 27, pp. E931-E939
Open Access | Times Cited: 1
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
Rosa Oh, Seohyun Kim, So Hyun Cho, et al.
Diabetes & Metabolism Journal (2024) Vol. 49, Iss. 1, pp. 80-91
Open Access | Times Cited: 1
Tenofovir versus entecavir on long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B
Kong Qing-yan, Qianqian Gao, Wenjie Li, et al.
Asian Journal of Surgery (2024) Vol. 47, Iss. 11, pp. 4725-4734
Open Access | Times Cited: 1
Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application
Lin Su, Jiawen Bu, Jiahui Yu, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 1
Familial clustering of MASLD: Rethinking strategies for population screening
Qiaoyue Ge, Zhenmi Liu
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. e289-e290
Open Access | Times Cited: 1
Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma
Adriano Pellicelli, Valerio Giannelli, Valerio Zoli, et al.
Clinical and Experimental Hepatology (2018) Vol. 4, Iss. 3, pp. 197-200
Open Access | Times Cited: 8
Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study
Peter Jepsen, Joe West, Anna Emilie Kann, et al.
Hepatology (2023) Vol. 80, Iss. 2, pp. 418-427
Closed Access | Times Cited: 2
MASLD co-aggregates with HCC in families-names change, fa(c)ts remain
Amedeo Lonardo
Hepatoma Research (2023)
Open Access | Times Cited: 2
Risk of Major Adverse Cardiovascular Outcomes in Families With MASLD: A Population-Based Multigenerational Cohort Study
Fahim Ebrahimi, Ramin Ebrahimi, Hannes Hagström, et al.
Circulation Cardiovascular Quality and Outcomes (2024) Vol. 17, Iss. 11
Closed Access
Page 1 - Next Page

Scroll to top